araag2/HINT huggingface dataset:
Clinical trial NCT00539240 (phase 2/phase 3, status: completed)
Conditions: gastroesophageal reflux disease
ICD codes: K21.9, K21.00, K21.01
Drugs: rabeprazole 20mg, placebo dinner and bedtime, rabeprazole 20 mg two times, placebo at bedtime, rabeprazole 20mg,placebo dinner ,low dose tricyclic antidepressant
SMILES: COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1, COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1, CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Currently being treated with a PPI, but continue to experience GERD symptoms (such as
             heartburn) at least 2 times per week.

        Exclusion Criteria:

          -  Known allergy or intolerance to TCA

          -  History of serious arrhythmia or use of anti-arrhythmics

          -  History of seizures

          -  Subjects with significant co-morbidity, e.g., cardiovascular, respiratory, urogenital,
             renal, gastrointestinal, hepatic, hematological, endocrine, neurologic or psychiatric

          -  With evidence or history of drug abuse within the past 6 months

          -  Erosive esophagitis, esophageal ulceration, peptic stricture, Barrett's esophagus or
             adenocarcinoma of the esophagus on endoscopy

          -  History of esophagogastric surgery

          -  Gastric or duodenal lesions (ulcer, tumor, etc.)

          -  Women who are pregnant or of childbearing age who are not on contraception

          -  Patients who are unwilling or unable to provide informed consent

          -  Insulin dependent diabetes
Clinical trial NCT01259050 (phase 1/phase 2, status: completed)
Conditions: amyotrophic lateral sclerosis
ICD codes: G12.21
Drugs: zinc and copper
SMILES: Cl[Cu]Cl
Eligibility criteria:

        Inclusion Criteria:

          1. Age 18-85

          2. Male or Female

          3. Clinically definite or probable ALS by El Escorial criteria

          4. ALS-FRS > 25

          5. If on Riluzole they must be on a stable dose for at least 30 days prior to screening

          6. Capable of providing informed consent and complying with trial procedures

        Exclusion Criteria:

          1. Patients with FVC below 50%

          2. History of liver disease

          3. Severe renal failure

          4. Creatinine greater than or equal to 1.5 mg/dL

          5. History of intolerance to zinc or copper

          6. Evidence of motor neuron disease for greater than 5 years

          7. Any other co-morbid condition which would make completion of the trial unlikely

          8. If female, pregnant or breast-feeding; or, if of childbearing age, an unwillingness to
             use birth control.

          9. Any other trial medications. Non-trial medications are not cause for exclusion

         10. Patient with history of significant anemia

         11. Elevated levels of zinc at baseline

         12. Patients with copper levels below normal at baseline
Clinical trial NCT00317044 (phase 2, status: completed)
Conditions: asthma, gerd
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: esomeprazole, esomeprazole, placebo
SMILES: COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1, COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adults with diagnosis of asthma since at least 6 months.

          -  Symptoms of asthma during run-in.

          -  At least 3 months history and present symptoms of 1 or more of the following: burning
             feeling behind breastbone, pain behind breastbone, acid taste in the mouth.

        Exclusion Criteria:

          -  Patients with clinically relevant abnormalities.

          -  Patients with a smoking history of ≥10 pack-year.

          -  Patients who have had previous surgery on the esophagus or the stomach.
Clinical trial NCT00497198 (phase 2, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: mci-196, placebo of mci-196 tablet
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients whose fasting blood glucose levels during the observation period are between
             130mg/dL and 200mg/dL.

          -  Patients whose HbA1c is 7.0% or above during the observation period.

        Exclusion Criteria:

          -  Patients with serious cardiac, hepatic or renal complications.

          -  Patients with serious diabetic complications.

          -  Patients with complete biliary obstruction or ileus.

          -  Pregnant, lactating, and probably pregnant patients, and patients who can not agree to
             contraception.
Clinical trial NCT00668785 (phase 2, status: terminated)
Conditions: proliferative diabetic retinopathy, macular edema
ICD codes: H35.23, H35.20, H35.21, H35.22, E10.3553, E11.3553, E13.3553, H59.033, H34.8130, H59.031, H59.032, H59.039, H34.8110, H34.8120
Drugs: ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Reason stopped: 
    study was terminated due to low enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Pre-PRP protocol refraction, fluorescein angiography, and optical coherence tomography
             AND 7-14 day post-PRP OCT

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age 21 years or older

          -  Previously untreated PDR patients with high risk characteristics who develop edema
             within 7-14 days post PRP therapy. This edema, determined by a masked investigator,
             will be characterized as either increased foveal thickness (>10% increase from pre-PRP
             foveal thickness), and/or increased macular volume on OCT (>10% increase from pre-PRP
             macular volume).

        Exclusion Criteria:

          -  Pregnancy (positive pregnancy test) prior to enrollment in the study

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated.

          -  Participation in another simultaneous medical investigation or trial

          -  Pre-PRP clinically significant diabetic macular edema (CSME) that would make the
             patient eligible for macular laser prior to PRP

          -  Neovascularization of the iris or neovascular glaucoma

          -  Increased central foveal thickness for any other reason

          -  Concurrent macular diseases that could confound the results of this study

          -  Prior vitrectomy in the study eye

          -  Prior treatment with intravitreal injection including pegaptanib sodium, ranibizumab,
             bevacizumab or triamcinolone acetonide
Clinical trial NCT00423098 (phase 2, status: completed)
Conditions: lupus nephritis
ICD codes: B26.83, A51.44, N11.8, N11.9, N12
Drugs: mycophenolate sodium, prednisone, methylprednisolone
SMILES: COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion criteria

          -  Male or female patients with systemic lupus erythematosus (SLE)(at least 4
             classification criteria)

          -  Aged ≥18 years,

          -  Proliferative lupus nephritis classified as ISN/RPS class III or IV

          -  Renal biopsy within the last 24-month preceding the study entry

          -  Proteinuria defined as >0.5 gram urine protein per gram urine creatinine at screening
             and baseline

          -  Clinical activity defined by one or more of the following changes in renal function:
             Serum creatinine >1.0 mg/dl (88.4 μmol/l)

          -  Microscopic hematuria defined as >5 red cells per high power field

          -  Presence of cellular casts

        Exclusion criteria

          -  Patients with calculated creatinine clearance <30 ml/min (using the Cockcroft-Gault
             formula)

          -  Patients having received an intravenous (i.v.) corticosteroid bolus during the last 3
             months,

          -  Patients having received oral or i.v. cyclophosphamide during the last 3 month

          -  Patients having received mycophenolate mofetil (MMF) within the preceding 3 months

          -  Use of any antibody therapy within the past 6 months

          -  Pregnant or nursing (lactating) women or women of child-bearing potential who are
             planning to become pregnant, or are not willing to use effective means of
             contraception throughout the study and during one month after the end of the study.

          -  Use of other investigational drugs within 1 month of enrollment (except for
             antibodies: within 6 months of enrollment

          -  History of hypersensitivity to any of the study drugs or to drugs with similar
             chemical structures,

          -  History of malignancy of any organ system, treated or untreated, within the past 5
             years whether or not there is evidence of local recurrence or metastases, with the
             exception of localized basal cell carcinoma of the skin.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT01005251 (phase 2, status: completed)
Conditions: gastroesophageal reflux disease, heartburn, regurgitation
ICD codes: K21.9, K21.00, K21.01, R12
Drugs: lesogaberan (azd3355), lesogaberan (azd3355), lesogaberan (azd3355), lesogaberan (azd3355), placebo
SMILES: NC[C@@H](F)CP(O)=O, NC[C@@H](F)CP(O)=O, NC[C@@H](F)CP(O)=O, NC[C@@H](F)CP(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Have at least 6 months history of GERD

          -  Continuously treated during the last 4 weeks before enrolment with daily optimized
             unchanged PPI therapy for any GERD indication

        Exclusion Criteria:

          -  Patients that have not experienced any GERD symptom improvement at all during PPI
             treatment

          -  Prior surgery of the upper gastrointestinal tract.

          -  Subject who have any of the following conditions or diseases: Heart disease, Angina,
             Seizure disorders such as epilepsy, Congestive Heart Failure (CHF), Liver disease such
             as Cirrhosis or Hepatitis, Kidney disease, Lung disease or lung cancer, Cancer
Clinical trial NCT00221637 (phase 2/phase 3, status: terminated)
Conditions: neuralgia, neuropathic peripheral pain
ICD codes: G50.0, M54.81, B02.22, M79.2
Drugs: sodium valproate
SMILES: CCCC(CCC)C(O)=O
Reason stopped: 
    slow recruitment and treatments beyond expiry date
  
Eligibility criteria:

        Inclusion Criteria:

          -  peripheral neuropathic pain

          -  signed written informed consent

        Exclusion Criteria:

          -  central neuropathic pain

          -  current or past hepatic disease
Clinical trial NCT01278134 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: copegus placebo, ro5024048, danoprevir, peginterferon alfa-2a [pegasys], ribavirin [copegus], ritonavir
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)C(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C, CC(C)(C)OC(=O)N[C@H]1CCCCC\C=C/[C@@H]2C[C@]2(NC(=O)[C@@H]2C[C@H](CN2C1=O)OC(=O)N1CC2=CC=CC(F)=C2C1)C(=O)NS(=O)(=O)C1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patient, >/= 18 years of age

          -  Chronic Hepatitis C of >/= 6 months duration at screening

          -  HCV genotype 1 and quantifiable HCV RNA at screening (Roche COBAS TaqMan HCV test)

          -  Naïve for treatment with interferon (pegylated or non-pegylated)

          -  Body Mass Index (BMI) 18-35 inclusive, minimum weight 45 kg

          -  Females of child-bearing potential and males with female partners of childbearing
             potential must use 2 forms of effective non-hormonal contraception

        Exclusion Criteria:

          -  Pregnant or lactating women and males with female partners who are pregnant or
             lactating

          -  Decompensated liver disease or impaired liver function

          -  Cirrhosis or incomplete/transition to cirrhosis

          -  Non-hepatitis C chronic liver disease

          -  Hepatitis B or HIV infection

          -  History of neoplastic disease within the last 5 years, except for localized or in situ
             carcinoma of the skin

          -  History of pre-existing renal disease (except for nephrolithiasis) or severe cardiac
             disease

          -  History of drug or alcohol abuse within the last year or alcohol consumption of > 2
             units per day; cannabinoid use is excepted
Clinical trial NCT00233363 (phase 2, status: completed)
Conditions: xerostomia, sjogren's syndrome
ICD codes: M35.00, M35.01, M35.03, M35.0B, M35.02, M35.05, M35.08
Drugs: rebamipide
SMILES: OC(=O)C(CC1=CC(O)=NC2=CC=CC=C12)NC(=O)C1=CC=C(Cl)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with Sjögren's syndrome (Revised Japanese criteria for Sjögren's syndrome
             (1999): 1998 research report on immunological intractable diseases specified by the
             Japanese Ministry of Health and Welfare)

          2. Patients aged 20 years or older at time of consent

          3. Patients with dry mouth

          4. Patients with decreased salivation

        Exclusion Criteria:

          1. Patients who have developed dry mouth clearly due to a cause other than Sjögren's
             syndrome

          2. Patients in whom Saxon test cannot be performed (artificial tooth, tooth implant,
             etc.)

          3. Patients who have received rebamipide within 3 months prior to obtaining informed
             consent

          4. Patients who are pregnant, possibly pregnant, or lactating

          5. Patients with a history of hypersensitivity to rebamipide

          6. Patients who have received any other investigational drug within 3 months prior to
             obtaining informed consent

          7. Patients who are otherwise judged inappropriate for inclusion in the study by the
             investigator or subinvestigator
Clinical trial NCT00242918 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: docetaxel, zd1839
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  prostate carcinoma: clinical stage T2b-3 or serum PSA>20 ng/ml or Gleason sum score
             8-10.

          -  clinical T2 patients are eligible if endorectal coil MRI shows T3 disease, or Gleason
             4+3 cancer in 5 or more biopsies (minimum of 10 biopsies total required)

          -  ECOG performance status of 0, 1 or 2

          -  adequate hematological, liver and renal function

          -  existing peripheral neuropathy < grade 1

          -  ability to tolerate oral medications.

        Exclusion Criteria:

          -  Concurrent or prior treatment with radiation, cytotoxic, biologic therapy for prostate
             cancer

          -  any major surgery within four weeks

          -  prior hormonal therapy (except finasteride for obstructive voiding symptoms- -evidence
             of metastatic disease, confirmed by physical examination, computed tomography of the
             abdomen and pelvis within 45 days and by bone scan within 60 days of signing informed
             consent
Clinical trial NCT01276548 (phase 2, status: completed)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: genexol®-pm 260mg/m2 plus carboplatin 5 auc, genexol® 175mg/m2 plus carboplatin 5 auc
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Subjects who aged 18 years or older

          2. Subjects whose written informed consent was obtained complying with the local
             regulatory requirements prior to their participation in the trial

          3. Subjects who have histologically or cytologically confirmed unresectable or metastatic
             epithelial cancer of the exocrine pancreas. High-quality contrast-enhanced CT scanning
             is required to evaluate resectability. Measurable disease is not required.

        Exclusion Criteria:

          1. Subjects who have received prior radiation therapy (XRT) for pancreatic cancer unless
             progression was documented after XRT and 6 weeks have elapsed between completion of
             XRT and start of trial medication.

          2. Subjects who have had systemic treatment such as chemotherapy or immunotherapy, for
             pancreatic cancer. However, prior use of chemotherapy, e.g. 5-FU or capecitabine, for
             radiation sensitization is allowed. If gemcitabine was given in the adjuvant setting,
             only subjects relapsed with cancer after 6 months of completing the last dose of
             gemcitabine can participate in the trial.

          3. Subjects who have had a major surgery within 2 weeks prior to the screening/baseline
             visit
Clinical trial NCT00612105 (phase 2, status: completed)
Conditions: postherpetic neuralgia
ICD codes: B02.22
Drugs: retigabine, placebo
SMILES: CCOC(=O)NC1=C(N)C=C(NCC2=CC=C(F)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Ability to provide informed consent

          -  Male or female subjects

          -  18-85 years of age

          -  PHN for more than 6 months after the healing of herpes zoster skin rash

          -  Has a pain score at screening and randomization that qualifies

        Exclusion Criteria:

          -  Other significant pain that may potentially confound PHN pain assessment

          -  Previous neurolytic or neurosurgical therapy for PHN

          -  Subject has evidence of a progressive central nervous system (CNS) disease (e.g. CNS
             lupus, tumors, multiple sclerosis, Alzheimer's), lesion, or encephalopathy

          -  Significant psychiatric or neuropsychiatric disorders including but not limited to
             severe depression, bipolar disorder or schizophrenia spectrum disorder, history of
             suicide attempt, or recent history of suicidal ideation

          -  Has clinically significant abnormalities on physical examination, vital signs, ECG, or
             laboratory tests at the screening visit
Clinical trial NCT00566397 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: pf-04494700, pf-04494700, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Mini Mental State Exam (MMSE) score between 14-26 (inclusive) at screening.

          -  Participants must be receiving acetylcholinesterase inhibitors on a stable dose for at
             least 4 months prior to randomization

        Exclusion Criteria:

          -  Current evidence or history of neurological, psychiatric and any other illness that
             could contribute to non-Alzheimer's dementia.

          -  Known history of familial AD or any evidence for early onset AD known or possibly
             associated with genetic mutations.

          -  Evidence or history of diabetes mellitus Type 1 or Type 2.

          -  History or symptoms of autoimmune disorders.
Clinical trial NCT00025272 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, etoposide, topotecan hydrochloride
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed extensive stage small cell lung cancer

          -  Measurable or evaluable disease

               -  Pleural effusions allowed, but not considered measurable or evaluable disease

          -  Brain metastases allowed provided neurologically stable at study entry

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  More than 2 months

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.5 mg/dL

        Renal:

          -  Creatinine no greater than 1.5 mg/dL

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Able to swallow capsules

          -  No concurrent or prior malignancy within the past 5 years except inactive
             nonmelanomatous skin cancer or carcinoma in situ of the cervix

          -  No other serious medical or psychiatric illness that would preclude study compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Prior radiotherapy for brain metastasis allowed

          -  No other prior radiotherapy

          -  No other concurrent radiotherapy

        Surgery:

          -  Not specified
Clinical trial NCT00630656 (phase 2, status: completed)
Conditions: severe sepsis
ICD codes: R65.20, R65.21
Drugs: talactoferrin alfa, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age greater than or equal to 18 years

          -  Onset of severe sepsis within the previous 24 hours

          -  Must be receiving antibiotic therapy

          -  Informed consent form signed by patient, legal next-of-kin or legal guardian

          -  Able to take medication by mouth or feeding tube

        Exclusion Criteria:

          -  Receipt of investigational medication within 4 weeks prior to participation in the
             study

          -  Pregnant or breast-feeding

          -  Severe congestive heart failure

          -  Known severe HIV infection

          -  Presence of severe burns

          -  Patients on high dose immunosuppressants

          -  Patients whose death is considered imminent

          -  Patients whose life expectancy for concurrent illness is less than 6 months

          -  Severe hypoxic encephalopathy or persistent vegetative state

          -  Severe liver disease

          -  Patient, legal representative or patient's primary physician not committed to
             providing full, aggressive life support